We are live on
!
Find out more
RMCM
Reynders McVeigh Capital Management Portfolio holdings
AUM
$1.98B
1-Year Est. Return
23.37%
This Fund
S&P 500
This Quarter
Est. Return
+14.94%
1 Year Est. Return
+23.37%
3 Year Est. Return
+85.22%
5 Year Est. Return
+113.19%
10 Year Est. Return
+523.93%
AUM
$2B
AUM Growth
+$212M
(+12%)
Cap. Flow
+$4.26M
Cap. Flow
% of AUM
0.21%
Top 10 Holdings %
Top 10 Hldgs %
39.9%
Holding
201
New
8
Increased
67
Reduced
103
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVO
Novo Nordisk
NVO
|
+$24.8M |
| 2 |
Unilever
UL
|
+$10.8M |
| 3 |
Rocket Companies
RKT
|
+$8.62M |
| 4 |
Salesforce
CRM
|
+$5.13M |
| 5 |
Applied Materials
AMAT
|
+$3.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$16.6M |
| 2 |
NVIDIA
NVDA
|
+$7.65M |
| 3 |
Automatic Data Processing
ADP
|
+$4.64M |
| 4 |
Aptiv
APTV
|
+$4.21M |
| 5 |
Tesla
TSLA
|
+$3.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.3% |
| 2 | Healthcare | 17.84% |
| 3 | Industrials | 16.88% |
| 4 | Consumer Discretionary | 9.64% |
| 5 | Communication Services | 7.68% |
Similar funds
SC
CAM
TCM
RCM
LGM
MYAM
NIM
C
Reynders McVeigh Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Reynders McVeigh Capital Management held 201 positions worth $2B, up 12% from $1.79B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Reynders McVeigh Capital Management's Q2 2025 filing shows 8 new, 67 increased, 103 reduced and 6 closed positions. Its largest new stake was Novo Nordisk: 363,889 shares worth $25.1M. The largest sale was Medtronic, an estimated $16.6M.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 33% a quarter earlier, followed by Healthcare and Industrials.
- Reynders McVeigh Capital Management's largest Q2 2025 buy was Novo Nordisk: 363,889 shares worth $25.1M.
- Reynders McVeigh Capital Management added most to Unilever in Q2 2025, an estimated $10.8M increase.
- Reynders McVeigh Capital Management's biggest Q2 2025 reduction was Medtronic, cutting an estimated $16.6M.
- Reynders McVeigh Capital Management fully exited Teradyne in Q2 2025, selling an estimated $1.26M.
- Reynders McVeigh Capital Management's ten largest holdings make up 40% of its $2B portfolio in Q2 2025.
- Reynders McVeigh Capital Management opened 8 new positions and closed 6 in Q2 2025.
- Reynders McVeigh Capital Management's portfolio value rose 12% quarter-over-quarter to $2B.
Based on Reynders McVeigh Capital Management's 13F filing for Q2 2025, filed 4 Sep 2025.